American Association for Cancer Research
Browse
15357163mct110884-sup-t1_pdf_62k.pdf (62.85 kB)

Supplementary Table 1 from HER2 As Therapeutic Target for Overcoming ATP-Binding Cassette Transporter–Mediated Chemoresistance in Small Cell Lung Cancer

Download (62.85 kB)
journal contribution
posted on 2023-04-03, 13:53 authored by Toshiyuki Minami, Takashi Kijima, Yasushi Otani, Satoshi Kohmo, Ryo Takahashi, Izumi Nagatomo, Haruhiko Hirata, Mayumi Suzuki, Koji Inoue, Yoshito Takeda, Hiroshi Kida, Isao Tachibana, Atsushi Kumanogoh

PDF file - 62K, Reversal effect of lapatinib on multidrug resistance. Cells (5�103 cells/well) were plated onto 96-well tissue culture-treated plates and treated with serially diluted cytotoxic drugs with or without lapatinib in serum containing medium for 72 h. The relative number of viable cells was quantified using CCK-8. IC50 concentration for each drug was calculated and presented as the mean � SD. Each experiment was done in triplicate and repeated at least thrice.

History

ARTICLE ABSTRACT

Small cell lung cancer (SCLC) easily acquires multidrug resistance after successful initial therapy. Overexpression of ATP-binding cassette (ABC) transporters is important for the multidrug resistance. Among them, ABCB1 and ABCG2 are known to be upregulated in chemoresistant SCLC cells. We found that human epidermal growth factor receptor 2 (HER2) expressions are also upregulated in chemoresistant SBC-3/ETP, SBC-3/SN-38, and SBC-3/CDDP cells, compared with chemosensitive SBC-3 cells. Lapatinib, a tyrosine kinase inhibitor of HER2, could not suppress proliferation of these HER2-positive SCLC cells alone but successfully restored chemosensitivity to etoposide and SN-38 with a clinically applicable concentration. The reversal effect of lapatinib was thought to be caused by inhibition of drug efflux pump functions of ABC transporters, although lapatinib itself has been reported to be a substrate for them. Moreover, knocking down of HER2 by an short interfering RNA weakened the effect of lapatinib on ABCB1, indicating the involvement of HER2 in the inhibitory mechanisms. Notably, we showed that caveolin-1 and Src play key roles in modulating ABCB1 function via HER2 inactivation. In SBC-3/ETP cells, dephosphorylation of HER2 by lapatinib activates Src and successively leads to increased caveolin-1 phosphorylation. Through this process, caveolin-1 dissociates from HER2 and strengthens association with ABCB1, and finally impairs the pump functions. Furthermore, we showed that treatment by lapatinib in combination with etoposide or irinotecan significantly suppresses the growth of subcutaneous SBC-3/ETP and SBC-3/SN-38 tumors in mice, respectively. Collectively, these results indicate that combination therapy with lapatinib and cytotoxic agents could conquer ABC transporter–mediated chemoresistance especially in HER2-positive SCLC. Mol Cancer Ther; 11(4); 830–41. ©2012 AACR.